Category:

Release – Orion Group Holdings, Inc. to Present at Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on December 4

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ORN

Nov 30, 2023

HOUSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, announced today that CEO Travis Boone and CFO Scott Thanisch will be participating in NobleCon 19 Emerging Growth Equity Conference being held at Florida Atlantic University in Boca Raton. Orion Management will be presenting on December 4, 2023, at 2:30 p.m. Eastern Time. Following the presentation there will be a breakout session with investors as well as scheduled one-on-one meetings.

A high-definition video webcast of the presentation will be available the following day on the Company’s website at https://www.oriongroupholdingsinc.com. The presentation will also be available on Noble Capital Markets’ Conference website www.nobleconference.com and on Channelchek www.channelchek.com, Noble Capital’s investor portal. The webcast will be archived for 90 days following the event.

About Orion Group Holdings
Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas. https://www.oriongroupholdingsinc.com.

About Noble Capital Markets, Inc. 
Noble Capital Markets (“Noble”) is a research-driven investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news. 

Contacts:

Financial Profiles, Inc.
Margaret Boyce 310-622-8247
mboyce@finprofiles.com

The GEO Group (GEO) – Senior Leadership Shuffle

Posted on by cpereira@noblefcm.com


Friday, December 01, 2023

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New CEO. Yesterday, GEO announced Brian Evans, who has been with the Company for 23 years and has served as the Company’s Chief Financial Officer for 14 years, has been appointed Chief Executive Officer, effective January 1, 2024. Current CEO Jose Gordo is transitioning to an advisor role, by mutual agreement. Given Mr. Evans’ familiarity with GEO and his strong performance as CFO, we believe this is a strong choice for the Company.

Zoley Term. Company founder and Executive Chairman George Zoley will step down as Executive Chairman as of June 30, 2026, the end of his current employment term. Mr. Zoley then will transition into the role as an advisor to the Company, while continuing to serve as the Company’s non-Executive Chairman of the Board of Directors.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Pfizer Weight Loss Pill Hits Snag in Mid-Stage Trial

Posted on by slightbourne@noblecapitalmarkets.com

Pharmaceutical giant Pfizer suffered a setback this week in the high-stakes race to tap into the burgeoning multi-billion dollar weight loss drug market. The company announced it is halting development of the twice-daily formulation of its experimental obesity pill danuglipron after underwhelming mid-stage trial results.

While the drug induced significant weight loss in obese patients, it came at the cost of poor tolerability. Over half of participants dropped out of the phase 2 study due to adverse gastrointestinal side effects like nausea and diarrhea.

Nonetheless, Pfizer still intends to stay in the game with a once-daily version of danuglipron. The company aims to release fresh phase 2 data on the more competitive formulation in early 2024 before determining next steps.

For a drugmaker grappling with fading Covid-19 revenues, the news deals a tough blow to its strategy to offset declines through potential new blockbusters for obesity. Just last year, CEO Albert Bourla tagged the total addressable weight loss market at a whopping $90 billion.

But competition is cutthroat, with Novo Nordisk and Eli Lilly vying to convert millions from their injectable diabetes meds to an oral option. Their rival pills have already posted mid-teens percentage weight loss results that position them to potentially leapfrog Pfizer’s attempt.

Danuglipron Quick Facts

  • Twice-daily formulation now discontinued after 6.9% to 11.7% weight loss at 32 weeks
  • Well below 14-15% loss seen as competitive threshold
  • High rates of nausea, vomiting, diarrhea
  • Over 50% dropout rate

Key Takeaways for Investors
The disappointing data for danuglipron’s twice-daily pill underscores several investor concerns around Pfizer’s efforts to expand into weight loss medicines.

Uphill Battle Against Rivals
Novo Nordisk and Eli Lilly already dominate the obesity drug landscape with their injectable products Saxenda and Ozempic. Lilly’s oral candidate tirzepatide is showing roughly 15% weight loss over 72 weeks, clearing the competitive bar Pfizer failed to hit.

While the field is large enough for multiple winners, Pfizer faces substantial share challenges from these deeply entrenched rivals. Its best-case outcome may be carving off a small slice rather than market leadership.

Tolerability Issues Limiting
Danuglipron has now faltered twice in mid-stage studies due to side effects leading over half of volunteers to quit treatment. The once-daily route shows some promise, but gastrointestinal problems may hamper uptake if they persist. By comparison, tirzepatide posted a 21% dropout rate.

Uncertainty Remains High
With phase 3 trials still a distant prospect, the program faces a long road ahead fraught with risk. While danuglipron evinced significant weight-loss efficacy, real-world commercial success depends greatly on improving its poor tolerability profile.

Until then, uncertainty around Pfizer’s weight loss aspirations stays high. Expect sales projections to remain muted absent positive late-stage outcomes down the line. But rivals like Lilly and Novo aren’t standing still either, making danuglipron’s path ahead even trickier.

Release – ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ZVSA

Nov 30, 2023

PDF Version

WESTON, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet needs, announces that its board of directors has approved a 1-for-35 reverse stock split of the Company’s common stock. The board of directors has also approved an increase in the Company’s authorized shares of capital stock. The Company’s stockholders approved the reverse stock split and the increase in authorized capital stock at the Company’s Annual Meeting of Stockholders held on October 31, 2023. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.

The reverse stock split will become effective on December 4, 2023 at 4:01 pm, Eastern Time, (“Effective Time”) and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Global Market (“Nasdaq”) on December 5, 2023 at market open under the existing ticker symbol, “ZVSA.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.

As of the Effective Time, every 35 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of our common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plans.

No fractional shares will be issued as a result of the reverse stock split; rather, the Company will issue an additional fraction of a share of common stock to round the number of shares to the nearest whole share, so no stockholder will hold fractional shares following the reverse stock split.

The Company’s transfer agent, Continental Stock & Trust Company, will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

Likewise, effective November 30, 2023, the Company amended its certificate of incorporation to increase the authorized number of shares of the Company’s capital stock from 111,000,000 to 251,000,000 and the number of authorized shares of common stock from 110,000,000 to 250,000,000.

Additional information about the reverse stock split and increase in authorized capital stock can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 13, 2023, a copy of which is available at www.sec.gov.

About ZyVersa Therapeutics

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the effect that the reverse stock split may have on the price of ZyVersa’s common stock and ZyVersa’s ability to maintain its listing on The Nasdaq Global Market.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Corporate and IR Contact:
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641

Media Contacts
Tiberend Strategic Advisors, Inc.
Casey McDonald
cmcdonald@tiberend.com
646-577-8520

Dave Schemelia
dschemelia@tiberend.com
609-468-9325

Release – Travelzoo Calls Travelers Worldwide to Make a Personal Pledge for Conscious Travel

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TZOO

NEW YORK/LONDON/TOKYO, November 30, 2023 — Safeguarding the future of travel begins with each of us. Travelzoo® (NASDAQ: TZOO), a global Internet media company, calls on travelers around the globe to make a personal #TravelforTomorrow pledge to become a conscious traveler.

The idea of #TravelforTomorrow is simple. A traveler makes a personal pledge of what they will do to travel more consciously. It could even be a small pledge, such as supporting local businesses, forgoing single-use plastic, choosing public transportation when possible, choosing off-the-beating path destinations, or respecting the local culture.

Travelers are asked to post their pledge on social media with the hashtag #TravelforTomorrow to demonstrate their commitment and inspire others.

Travelzoo employees, at the global company meeting in Venice, Italy, set a goal of reaching 10,000 pledges from travelers by December 31.

Travelzoo invited protagonists Freya Air Aspinall, Michela Bortolozzi, Christian Delom, Jerome Foster II, Yumika Hoskin, and Anna Spenceley to its company meeting.

Travelzoo

590 Madison Avenue 35th Floor

New York, NY 10022

Media contacts: Paige Cram – Los Angeles +1 609 668 0645 pcram@travelzoo.com

Cat Jordan – London +44 7776 781525 cjordan@travelzoo.com

Hajime Suzuki – Tokyo +81 3 6380 6741 hsuzuki@travelzoo.com

Learn how to make a personal pledge: http://www.travelfortomorrow.com.

About #TravelforTomorrow

#TravelforTomorrow calls travelers worldwide to make a personal pledge for conscious travel. It could even be a small pledge, such as supporting local businesses, forgoing single-use plastic, choosing public transportation when possible, choosing off-the-beating path destinations, or respecting the local culture. #TravelforTomorrow is a non-profit initiative from Travelzoo.

Release – The GEO Group Announces Senior Management Changes

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GEO

November 30, 2023

PDF Version

BOCA RATON, Fla.–(BUSINESS WIRE)–Nov. 30, 2023– The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that following discussions between GEO and its Chief Executive Officer, Jose Gordo, the parties have agreed that Mr. Gordo will be departing as Chief Executive Officer and as a Board member on mutually agreeable terms and transitioning to the role of an advisor, effective December 31, 2023. Under the agreed terms of his departure, Mr. Gordo will enter into a fixed, 18-month advisory services agreement upon payment terms agreed to by the parties, pursuant to which Mr. Gordo will advise the Company with respect to litigation, client relations, operational issues, growth opportunities, financial management, and debt restructuring. The Company is seeking to continue Mr. Gordo’s services in these specific areas to benefit from his many years of experience in the industry, the deep relationships he has forged inside the Company and with its industry partners, his global operating perspectives, and his specific expertise in a specialized industry.

Brian Evans, who has been with the Company for 23 years and has served as the Company’s Chief Financial Officer for 14 years, has been appointed Chief Executive Officer, effective January 1, 2024. Shayn March, Executive Vice President, Finance and Treasurer, has been appointed Acting Chief Financial Officer, effective January 1, 2024. The Company and its Board of Directors will work with an external search firm to identify a permanent Chief Financial Officer.

Also effective January 1, 2024, Wayne Calabrese has been appointed President and Chief Operating Officer. Mr. Calabrese joined the Company in 1989, retiring as its President and Chief Operating Officer at the end of 2010. Following his service as a Company advisor, Mr. Calabrese rejoined the Company on a full-time basis in 2021 as head of the Legal Department. In 2022, Mr. Calabrese was appointed to his current position as Senior Vice President and Chief Operating Officer.

In addition, the Company confirmed that Dr. George Zoley, the Company’s Founder and Executive Chairman, will step down as Executive Chairman on June 30, 2026, at the end of his current employment term under his Executive Chairman Employment Agreement. Beginning on July 1, 2026, Dr. Zoley will continue his unparalleled 40-plus year industry leadership role as an Advisor to the Company while continuing to serve as the Company’s non-Executive Chairman of the Board of Directors, subject to shareholder approval.

About The GEO Group

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 100 facilities totaling approximately 81,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Use of forward-looking statements

This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2022, its Form 10-Qs for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, and its Form 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

Pablo E. Paez, (866) 301 4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Inflation Edges Higher in October but Shows Ongoing Signs of Cooling

Posted on by slightbourne@noblecapitalmarkets.com

New government data released Thursday indicates that inflation ticked slightly higher in October but remained on a broader cooling trajectory as price pressures continue moderating from 40-year highs reached earlier this year. The report provides further evidence that the rapid pace of price increases may be starting to steadily decelerate, supporting the Federal Reserve’s recent inclination to halt its aggressive interest rate hike campaign.

The Fed’s preferred inflation gauge, the core personal consumption expenditures (PCE) price index, rose 0.2% last month and 3.5% over the past year. This matched consensus economist forecasts. The core PCE index strips out volatile food and energy costs to provide a clearer view underlying price trends.

While still well above the Fed’s 2% target, the annual increase was down from 5.3% in February. The incremental monthly gain showed prices climbing at a more restrained pace after an intense burst earlier this year.

“The Fed is on hold for now but their pivot to rate cuts is getting closer,” said Bill Adams, chief economist at Comerica Bank. “Inflation is clearly slowing.”

Markets are already betting policymakers won’t hike rates again this cycle, and may even start cutting in 2024 to bolster growth as price pressures continue easing. The latest data provides credibility to the idea that the Fed’s rapid rate hikes since March, which have raised its benchmark to a 15-year high, have begun achieving their intended effect of reining in demand and cooling the economy enough to tame inflation back toward manageable levels.

Still Cautious on Further Easing

However, Fed officials stressed that rates will still need to remain at restrictive levels for some time to ensure inflation continues descending toward the central bank’s 2% target.

New York Fed President John Williams said Thursday he expects inflation to keep drifting lower, finally hitting the Fed’s goal by 2025. But he emphasized rates will likely need to stay elevated until then to completely quell price pressures.

Other Fed policymakers also struck a cautious tone on prematurely ending rate hikes before inflation is convincingly on a path back towards the 2% goal. Many noted that while price increases may be peaking, inflation remains stubbornly high and consumer demand continues holding up more than feared despite rapid rate rises this year.

Moderating Labor Market Could Allow Rate Cuts

There were some early signs in Thursday’s data that the torrid job market may also finally be cooling slightly after persisting at unsustainable levels through much of the year.

The report showed continuing jobless claims climbed to 1.93 million in mid-November, their highest mark since November 2021. The number of Americans applying for ongoing unemployment benefits has risen by more than 80,000 since October.

While still historically low, the increase could provide Fed officials confidence that their rate hikes have begun not only slowing demand and price growth, but also easing excessively tight labor market conditions they have said contributed to rapid wage and inflation surges.

An easing job market that reduces wage pressures could give the Fed leeway next year to shift their priority toward sustaining growth and cut rates to spur a slowing economy, especially as other inflationary pressures subside.

Consumers Keeping Pace For Now

On the growth side, the report showed some signs of resilience among consumers even in the face of elevated inflation and rising borrowing costs.

Personal income and consumer spending both edged up 0.2% in October, indicating households are so far keeping pace with rising prices digging into their paychecks. Services like travel and healthcare saw particularly solid spending last month.

Surveys show consumers remain relatively upbeat thanks to still-ample savings and solid income growth. But many Fed officials have noted anecdotally that households appear to be pulling back spending more than aggregate data indicates so far. Any sharper-than-expected deceleration in consumer demand would give policymakers leeway to pivot toward supporting growth.

Eyes on Services Inflation

Some economists noted that while goods prices have cooled sharply from peaks last year amid improving supply issues, services costs remain stubbornly high for now as resilience in consumer demand combined with rising wage growth enables firms to pass higher labor expenses to customers.

“Inflation is moderating with goods prices leading the charge,” said economist Nancy Vanden Houten of Oxford Economics. But she said core services costs actually ticked up in October, bearing monitoring to ensure price stability as the economy shifts more toward services consumption over goods.

With strong income gains and accumulated savings still underpinning spending for now, officials emphasized rates may need to stay higher for longer to ensure the progress made on easing price pressures sticks.

“I expect it will be appropriate to maintain a restrictive stance for quite some me to fully restore balance and to bring inflation back to our 2 percent longer-run goal on a sustained basis,” said the New York Fed’s Williams on Thursday.

AdTheorent (ADTH) – Positioned To Outshine Favorable Industry Growth

Posted on by cpereira@noblefcm.com


Thursday, November 30, 2023

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating and $4 price target. AdTheorent is a privacy-forward, programmatic advertising company that uses cutting edge, machine-learning technology to deliver targeted ad campaigns. We believe the company has meaningful technology advantage over many of its peers, which may rely on user IDs and third-party cookies, explained in this report. Our favorable rating is based on our positive cash flow growth outlook for the company.  

Ahead of the curve. Through its proprietary machine learning technology, the company’s demand-side platform (DSP) uses anonymized data points to create predictive algorithms to target digital audiences. Given Google’s indication that it will be phasing out the use of third-party cookies, AdTheorent’s ML technology could be a significant competitive advantage in the digital advertising industry going forward.  


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Century Lithium Corp. (CYDVF) – Major Catalysts on the Horizon

Posted on by cpereira@noblefcm.com


Thursday, November 30, 2023

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Feasibility study expected by year-end. During the third quarter, Century Lithium focused on pilot plant operations and completing the Clayton Valley Lithium Project feasibility study which is expected by year-end. Estimates for the feasibility study have been updated based on optimization and evaluation of economic scenarios, including the start-up schedule and potential by-products, including sodium hydroxide. Most of the work remaining is focused on completion of the economic model, sensitivity analysis, and finalizing capital and operating costs.

Collaboration with Koch. Century’s collaboration with Koch Technology Solutions on the direct lithium extraction (DLE) section of the pilot plant continues with results to date meeting expectations. The company has achieved an average lithium recovery rate of 85% and average DLE recovery greater than 99.5% with continued success in producing battery grade lithium carbonate from pilot plant solutions treated at Saltworks Technologies Inc.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Entravision Announces Participation in NobleCon19 – Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference

Posted on by aweinsoff@channelchek.com

Research News and Market Data on EVC

November 29, 2023

Download(opens in new window)

SANTA MONICA, Calif.–(BUSINESS WIRE)– Entravision (NYSE: EVC), a leading global advertising solutions, media and technology company, today announced its participation in NobleCon19, Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference, to be held December 3-5, 2023, in Boca Raton, FL. Chris Young, Chief Financial Officer and Treasurer, is scheduled to present on Monday, December 4th, 2023 at 11:30 a.m. ET and will participate in meetings with investors throughout the day.

A high-definition video webcast of the presentation will be available the following day on Entravision’s Investor Relations website at investor.entravision.com.

About Entravision Communications Corporation

Entravision is a global advertising solutions, media and technology company. Over the past three decades, we have strategically evolved into a digital powerhouse, expertly connecting brands to consumers in the U.S., Latin America, Europe, Asia and Africa. Our digital segment, the company’s largest by revenue, offers a full suite of end-to-end advertising services in 40 countries. We have commercial partnerships with Meta, X Corp. (formerly known as Twitter), TikTok, and Spotify, and marketers can use our Smadex and other platforms to deliver targeted advertising to audiences around the globe. In the U.S., we maintain a diversified portfolio of television and radio stations that target Hispanic audiences and complement our global digital services. Entravision remains the largest affiliate group of the Univision and UniMás television networks. Shares of Entravision Class A Common Stock trade on the NYSE under ticker: EVC. Learn more about our offerings at entravision.com or connect with us on LinkedIn and Facebook.

Christopher T. Young
Chief Financial Officer
Entravision
310-447-3870

Kimberly Orlando
Addo Investor Relations
310-829-5400
evc@addo.com

Source: Entravision

Release – The ODP Corporation to Present at the Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference Monday, December 4th, 2023

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ODP

PDF Version

BOCA RATON, Fla.–(BUSINESS WIRE)–Nov. 29, 2023– The ODP Corporation (“ODP,” or the “Company”) (NASDAQ:ODP), a leading provider of business services, products and digital workplace technology solutions to businesses and consumers, announced today that D. Anthony Scaglione, executive vice president and chief financial officer, and Tim Perrott, vice president of investor relations and treasurer, will present at the Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference on December 4th, 2023 at approximately 3:00 pm (ET).

A replay of the presentation will be available the following day on the Company’s investor relations website, investor.theodpcorp.com.

About The ODP Corporation
The ODP Corporation (NASDAQ:ODP) is a leading provider of products, services, and technology solutions through an integrated business-to-business (B2B) distribution platform and omni-channel presence, which includes world-class supply chain and distribution operations, dedicated sales professionals, a B2B digital procurement solution, online presence, and a network of Office Depot and OfficeMax retail stores. Through its operating companies Office Depot, LLC; ODP Business Solutions, LLC; Veyer, LLC; and Varis, Inc., The ODP Corporation empowers every business, professional, and consumer to achieve more every day. For more information, visit theodpcorp.com.

ODP and ODP Business Solutions are trademarks of ODP Business Solutions, LLC. Office Depot is a trademark of The Office Club, LLC. OfficeMax is a trademark of OMX, Inc. Veyer is a trademark of Veyer, LLC. Varis is a trademark of Varis, Inc. Grand&Toy is a trademark of Grand & Toy, LLC in Canada. ©2023 Office Depot, LLC. All rights reserved. Any other product or company names mentioned herein are the trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129222778/en/

Tim Perrott
Investor Relations
561-438-4629
Tim.Perrott@theodpcorp.com

Source: The ODP Corporation

Release – Eledon Pharmaceuticals to Present at Noble Capital Markets’ Emerging Growth Equity Conference

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ELDN

November 29, 2023

PDF Version

IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCon19 – Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4, 2023, at 12:00 p.m. EST. Dr. Gros will also participate in a panel discussion titled: The Organ Transplant Revolution, that will take place on Monday, December 4, 2023, at 5:00 p.m. EST. The NobleCon19 conference will take place December 3-5, 2023, in Boca Raton, Florida.

A video webcast of the company overview presentation will be available the following day on the Company’s website at https://ir.eledon.com/news-and-events/events, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek: www.channelchek.com, the investor portal created by Noble. The webcast will be archived on Eledon’s website, the NobleCon website, and on Channelchek.com for 90 days following the event.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals

Release – Kelly to Participate in the 19th Annual Noble Capital Markets Emerging Growth Equity Conference

Posted on by aweinsoff@channelchek.com

Research News and Market Data on KELYA

November 29, 2023

TROY, Mich., Nov. 29, 2023 /PRNewswire/ — Kelly (Nasdaq: KELYA, KELYB), a leading global specialty talent solutions provider, today announced it will participate in the 19th Annual Noble Capital Markets Emerging Growth Equity Conference at Florida Atlantic University in Boca Raton, Florida, on Monday, December 4, 2023, and Tuesday, December 5, 2023.

Peter Quigley, president and chief executive officer, Olivier Thirot, executive vice president and chief financial officer, Nicola Soares, president of Kelly Education, and Scott Thomas, investor relations, will participate in one-on-one meetings. Kelly’s investor presentation is available on the company’s website.

About Kelly®

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 450,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2022 was $5.0 billion. Learn more at kellyservices.com.

KLYA-FIN

ANALYST & MEDIA CONTACT:
Scott Thomas
(248) 251-7264  
scott.thomas@kellyservices.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kelly-to-participate-in-the-19th-annual-noble-capital-markets-emerging-growth-equity-conference-302000862.html

SOURCE Kelly Services, Inc.